In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.
Completed
Conditions studied: Anesthesia
In brief
Oxytocin is normally administered following delivery in pregnant patients to reduce postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to assess the coagulation changes of oxytocin in blood samples from pregnant patients using thromboelastrography (TEG). TEG is a point-of-care device which measures the viscoelastic properties of clot formation, and can provide rapid and detailed information about coagulation changes. We aim to collect blood samples from pregnant patients to assess the in-vitro effects of synthetic oxytocin on coagulation using TEG.
Key facts
- Study ID
- NCT00788255
- Run by
- Stanford University
- People needed
- 25
- Starts
- 2008-10-01
- Expected to finish
- 2009-06-01
- Last updated by the study team
- 2016-11-28
Who can join
Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.